Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Erythrocyte–antibody conjugates to overcome immunotherapy resistance
Urvashi Mitbander Joshi
,
Rodabe N. Amaria
Melanoma Medical Oncology
Research output
:
Contribution to journal
›
Comment/debate
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Erythrocyte–antibody conjugates to overcome immunotherapy resistance'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Immunotherapy Resistance
100%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
100%
Solid Tumors
50%
Patients with Cancer
50%
Safety Data
50%
Efficacy Data
50%
Phase 1 Trial
50%
Antitumor Immune Response
50%
Overcoming Resistance
50%
Resistance to Immune Checkpoint Inhibitors
50%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Neoplasm
100%
Malignant Neoplasm
100%
Immunotherapy
100%
Immune Checkpoint Inhibitor
100%